CRISPRSYSTEM

Identification and Characterization of Host and Phage Proteins Interacting with the CRISPR System

 Coordinatore TEL AVIV UNIVERSITY 

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Ms.
Nome: Einat
Cognome: Ron
Email: send email
Telefono: +972 3 6406240
Fax: +972 3 6405598

 Nazionalità Coordinatore Israel [IL]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-RG
 Funding Scheme MC-IRG
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-06-01   -   2014-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Ms.
Nome: Einat
Cognome: Ron
Email: send email
Telefono: +972 3 6406240
Fax: +972 3 6405598

IL (TEL AVIV) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

resistance    genetic    host    mechanism    confer    defense    identification    yet    genetically    unknown    heterologous    prokaryotic    proteins    dna    participate    bacterial    crispr    libraries    crisprsystem    genes    human    screens    plasmids    platform    found    coli    components    phage    scientists    recent    recently    cas    sequences    gene    phages    immune   

 Obiettivo del progetto (Objective)

'The CRISPR system was recently identified as a bacterial defense mechanism against phages and plasmids. The CRISPR system is composed of DNA arrays containing short sequences identical to those present in phages and plasmids. These short DNAs are transcribed and processed by CRISPR associated proteins that also guide other CRISPR proteins to target the invading DNA. Only a few of the CRISPR components have been characterized to date and their mechanism of action is still largely unknown. Phage defense mechanisms probably have co-evolved against the CRISPR system, but none have yet been found. We propose to identify phage genes that counteract the CRISPR system. We will utilize screens that make use of the bacterial version of the yeast two-hybrid genetic system, phage genomic libraries, and biochemical assays to identify phage genes that help phages evade the CRISPR system. The candidate genes will be characterized both genetically and biochemically to allow structural studies of their interactions with the CRISPR system. These genes will then be cloned into commercial phages that are used to kill bacterial pathogens so that the phages acquire resistance to the CRISPR defense mechanism. We also propose to identify the yet unknown E. coli proteins that participate in the activity of the CRISPR system by using genetic screens of transposon insertion mutant libraries. The identification of novel proteins that participate in the CRISPR system will constitute a significant step toward the ultimate goal of reconstituting the complete system from purified proteins. Finally, we propose to clone all the components of the E. coli CRISPR system and render them functional in heterologous prokaryotic organisms such as attenuated strains of Salmonella, Shigella and more distantly related species such as Streptococci. Cloning the genes of the E. coli CRISPR system into heterologous bacteria will allow us to genetically address the role of each gene.'

Introduzione (Teaser)

The recent breakthrough applications of the CRISPR/Cas bacterial immune system urged European scientists to study its features in-depth.

Descrizione progetto (Article)

A recent discovery unveiled the existence of a prokaryotic immune defence mechanism that confers resistance to foreign genetic elements such as phages. The so-called CRISPR/Cas system is based on the recognition of specific DNA sequences known as CRISPRs (clustered regularly interspaced short palindromic repeats) by the CAS nucleases.

Researchers realised the power of the system at gene editing and have successfully utilised it to genetically manipulate human DNA. As a result, the CRISPR/Cas system holds great prospects for human health, as well as in numerous biotechnological applications.

The EU-funded 'Identification and characterization of host and phage proteins interacting with the CRISPR system' (CRISPRSYSTEM) project focused on delineating basic aspects of the system. Using an experimental platform established in the host lab, project scientists studied the CRISPR adaptation process. Their work aimed to identify which proteins, DNA elements and steps are required for the process to work.

They discovered a novel element in sequences acquired to confer immunity against bacteriophages. This element enhanced the acquisition of these sequences into the CRISPR array. In addition, a new protein for the system's immune function was found.

Furthermore, the project showed that the activity of the CRISPR/Cas system extends to confer protection against lysogens and prophages. This led the research team to develop a new platform for modifying bacteriophage genomes using the CRISPR/Cas system.

Taken together, the activities of CRISPRSYSTEM significantly advanced knowledge on the recently described bacterial CRISPR/Cas system. Given the system's promising applications, the new information opens up more avenues of exploitation of this revolutionary approach.

Altri progetti dello stesso programma (FP7-PEOPLE)

3DNET (2013)

Drug Discovery and Development for Novel Eye Therapeutics

Read More  

NOMOS (2013)

"Novel semiconductor Optical sources for Metrology, Signal PrOcessing and Space applications."

Read More  

RP11MOUSE (2009)

Validation of the disease model and therapy for retinitis pigmentosa 11

Read More